Developing a model to predict risks of iodine contrast medium extravasation
Official title: Development and Validation of a Risk Prediction Model for Iodinated Contrast Medium Extravasation in Patients Undergoing Contrast-enhanced Computed Tomography
Run by Tongji Hospital · NCT06859242 · Data updated 2026-11-12
This study is trying to create a tool to help doctors predict which patients might have problems with iodine contrast during CT scans, so they can manage the risks better.
Quick facts
| Study type | Observational |
|---|---|
| Sex | All |
| Enrollment | 1000 (estimated) |
| Sponsor | Tongji Hospital Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Wuhan, Hubei) |
| Status | Recruiting |
| Started | January 25, 2025 |
| Main results expected | May 31, 2026 |
| Study ends | November 30, 2026 |
| Registry record updated | March 5, 2025 |
| Trial ID | NCT06859242 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are patients undergoing enhanced CT examinations who are willing to participate and do not have contraindications to iodine contrast.
✕Probably not a fit
Patients with iodine contrast allergies, hyperthyroidism, or those in critical condition may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to create a risk prediction model for iodine contrast agent extravasation during enhanced CT examinations. It employs a retrospective case-control design, comparing patients who experienced extravasation with those who did not. Data collected includes demographic information, medical history, examination parameters, venous access details, and environmental factors. The goal is to implement this model clinically to enhance risk management for iodine contrast agent extravasation.
Why it matters
Potential benefit: If successful, this model could significantly reduce the incidence of iodine contrast medium extravasation and improve patient safety during CT examinations.
How similar studies have gone: While similar predictive models have been explored, this specific approach to iodine contrast extravasation is novel and has not been extensively tested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Volunteer to participate in this study. 2. Without contraindications such as iodine contrast allergy or hyperthyroidism. - Exclusion Criteria: 1. There are communication barriers between researchers and patients. 2. Due to critical condition or unstable vital signs, patients should be transferred to relevant clinical departments for treatment or observation immediately after examination.
Where it's running
-
TongjiHospital
Wuhan, Hubei, China Recruiting
Study contacts
- Principal investigator: Wenyan Zhang, Master — Tongji Hospital
- Study coordinator: Wenyan Zhang, Master
- Email: callmeanna1986@163.com
- Phone: 0086-027-83663493
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
ePRO in advanced lung cancer: emotional distress, brain metastasis, and symptom burden
This study tests how patients with advanced lung cancer—some with brain metastases—report emotional distress and symptoms over time using electronic questionnaires.
-
Zhixuan Analgesic Tablet for frequent tension-type headaches
A randomized trial tests whether Zhixuan Analgesic Tablet, taken three times daily for 12 weeks, can reduce headache days in adults with frequent episodic tension-type headaches compared with a placebo.
-
Rimegepant for acute vestibular migraine in adults
This study tests whether a first dose of rimegepant followed by a second dose of placebo, or first dose placebo followed by a second dose of rimegepant, helps relieve acute vestibular symptoms in adults with vestibular migraine.
-
Cardiorespiratory fitness after lobectomy versus sublobar resection in NSCLC
This study tests how different lung surgeries (lobectomy vs. sublobar resection) affect fitness levels after surgery in people with non-small cell lung cancer.
-
MRI plus diffusion and CEST imaging to map liver cancer and its immune environment
This study tests whether adding an extra MRI sequence can help see how the liver cancer microenvironment changes and relate those changes to immune activity in patients with hepatocellular carcinoma.
-
Postoperative EGFR-TKI Therapy for EGFR-mutant NSCLC Following Surgery
This registry tests whether giving an EGFR-TKI after surgery helps adults with EGFR-mutant, high-risk early-stage NSCLC.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.